CompletedPhase 3NCT00400478
A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13
Studying Aggressive B-cell non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Principal Investigator
- Ulrich Jaeger, Prof. Dr.Medical University of Vienna
- Intervention
- Rituximab(drug)
- Enrollment
- 683 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2006 – 2013
Study locations (30)
- Border Medical Oncology, Wodonga, Victoria, Australia
- Concord Repatriation General Hospital, Concord, Australia
- Gosford Hospital, Gosford, Australia
- Greenslopes Hospital, Greenslopes, Australia
- Prince of Wales Hospital, Sydney, Australia
- Krankenhaus Oberpullendorf, Oberpullendorf, Burgenland, Austria
- Krankenhaus Oberwart, Oberwart, Burgenland, Austria
- A.ö. Krankenhaus der Landeshauptstadt St. Pölten, Sankt Pölten, Lower Austria, Austria
- A.ö. Krankenhaus der Statutarstadt Wr. Neustadt, Wiener Neustadt, Lower Austria, Austria
- St. Johanns LK, Salzburg, Salzburg, Austria
- A.ö. Landeskrankenhaus Steyr, Steyr, Styria, Austria
- Bezirkskrankenhaus Kufstein, Endach, Tyrol, Austria
- A.oe.Bezirkskrankenhaus Hall, Hall in Tirol, Tyrol, Austria
- Universitätsklinik Innsbruck/ Klinik für Innere Medizin, Innsbruck, Tyrol, Austria
- Krankenhaus d. Barmherzigen Schwestern Linz, Linz, Upper Austria, Austria
- +15 more locations on ClinicalTrials.gov
Collaborators
Hoffmann-La Roche
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00400478 on ClinicalTrials.govOther trials for Aggressive B-cell non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT07474051Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical TrialsAvenCell Therapeutics, Inc.
- RECRUITINGEARLY PHASE1NCT07344818An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell LymphomaPeking University People's Hospital
- RECRUITINGPHASE2NCT07097363Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin LymphomaUniversity of Washington
- RECRUITINGPHASE2NCT06649812Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2, PHASE3NCT07168980Chemotherapy With Rituximab for Aggressive B-NHL in Children and AdolescentsChildren's Cancer Group, China
- RECRUITINGPHASE2NCT06996132Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell LymphomaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT06834373Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell TherapyMayo Clinic
- RECRUITINGPHASE1, PHASE2NCT06536049Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin LymphomaYazeed Sawalha